Announcement on stabilization measures in OssDsign AB (publ) during the period from June 17 to June 20, 2019 and termination of the stabilization period

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR OTHER COUNTRIES WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE PERMITTED OR REQUIRE REGISTRATION OR OTHER MEASURES

Erik Penser Bank AB (”EPB”) announces that stabilization measures have been undertaken in OssDsign AB’s (publ) (”OssDsign” or the ”Company”) shares on Nasdaq First North. EPB also announces that the stabilization period, which started on May 24, 2019, today has ended and no further stabilization transactions will be undertaken. During the stabilization period, stabilization purchases amounted to a total of 825,000 shares, which implies that the over-allotment option will not be exercised.

As announced in connection with the offer to acquire newly issued shares in the Company and the listing of the Company's shares on Nasdaq First North (the "Offer"), EPB has had the possibility, in its capacity as stabilization manager, to carry out transactions in order to support the market price of the shares at a higher level than what might otherwise prevail in the market.

There has been a possibility to undertake stabilization measures on Nasdaq First North, the OTC market or otherwise during the period that started on the first day of trading in the shares on Nasdaq First North, that is, May 24, 2019, and that ended no later than 30 calendar days thereafter. However, EPB has had no obligation to undertake any stabilization measures and has not provided any guarantees that stabilization measures will be undertaken. Stabilization measures that have been initiated have been able to be discontinued at any time without prior notice. Transactions have under no circumstances been carried out at a price that is higher than the price in the Offer.

Moreover, OssDsign has, within the Offer, issued an option to EPB, which may be exercised in whole or in part, to subscribe for 825,000 newly issued shares in the Company, corresponding to a maximum of 15 percent of the number of newly issued shares in the Offer, at a price corresponding to the price in the Offer, SEK 27.50, to cover any over-allotment in connection with the Offer. EPB announces that the over-allotment option will not be exercised.

EPB has, in its capacity as stabilization manager, announced that stabilization measures have been undertaken, in accordance with Article 5(4) of the EU Market Abuse Regulation 596/2014, on Nasdaq First North, as below. Contact person at EPB is Oskar Ekman, tel: +46 8 463 80 36.

Stabilization information

Issuer: OssDsign AB (publ)

Securities: Shares (ISIN SE0012570448)

Offer size: 6,325,000 shares of which stabilization constitutes a maximum of 825,000 shares

Offer price: 27.50 SEK per share

Ticker: OSSD

Stabilization manager: Erik Penser Bank AB (publ)

Below is a summary of the stabilization transactions that have been undertaken during the period from June 17 to June 20, 2019. All transactions during the stabilization period have been undertaken on Nasdaq First North.

Stabilization transactions

Termination of the stabilization period

The stabilization period for the Offer has now been terminated and no further stabilization transactions will be undertaken. Below is a summary of the stabilization transactions that have been undertaken during the stabilization period. All transactions during the stabilization period have been undertaken on Nasdaq First North and no stabilization measures have been undertaken on dates other than those listed below.

Certified Adviser
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08, email: al@ossdsign.com 

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 17:45 CET on June 20, 2019

Tags: